Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | CTSC | P53634 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7306083 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL7340749 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL7340833 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL6329133 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL26120460 | 0.98 | CYP2D6 (0.50) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL26116451 | 0.98 | CYP2D6 (0.50) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL20604369 | 0.86 | CYP2D6 (0.50) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL13422396 | 0.83 | CTSC (0.50) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL24021118 | 0.82 | CTSC (0.49) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL29063455 | 0.82 | CTSC (0.49) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926295-B2 | Potent and selective inhibitors of hepatitis C virus | COCRYSTAL PHARMA, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3131892-A2 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | Cocrystal Pharma, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20170029407-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | EMORY UNIVERSITY | 2017-02-02 | — | — | US | disclosed |
| WO-2015160907-A2 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | COCRYSTAL PHARMA, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-6329502-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | JAPAN ENERGY CORPORATION (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6313094-B1 | COMPOSITION FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | JAPAN ENERGY CORPORATION (JP) | 2001-11-06 | — | — | US | disclosed |
| US-6291432-B1 | (R)-N-(2-METHYLBENZYL)-3-((2S, 3S)-3-(N-(2-CHROMONECARBONYL)-L-ASPARAGINYL)AMINO-2-HYDROXY-4-PHENYLBUTANO YL)-5,5-DIMETHYL-1,3-THIAZOLIDINE-4-CARBOXAMIDE CAN BE GIVEN AS A TYPICAL EXAMPLE OF THIS COMPOUND. | JAPAN ENERGY CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0490667-B1 | HIV protease inhibitors | JAPAN ENERGY CORP (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0900566-A1 | NOVEL TRIPEPTIDE COMPOUNDS AND ANTI-AIDS DRUGS | JAPAN ENERGY CORPORATION (JP) | 1999-03-10 | — | — | EP | disclosed |
| EP-0490667-A2 | HIV protease inhibitors | JAPAN ENERGY CORPORATION (JP) | 1992-06-17 | — | — | EP | disclosed |
| US-4766110-A | INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS | RYAN JAMES W (US) | 1988-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029407-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, PYGL | CYP2D6 567/4885CYP1A2 326/4885ALOX15 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.